Cargando…

Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study

Detalles Bibliográficos
Autores principales:	Garratt, C, Packer, M, Colucci, W, Fisher, L, Massie, B, Teerlink, J, Young, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2004
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099676/ http://dx.doi.org/10.1186/cc2556

Ejemplares similares

The ADHERE classification and regression tree model overestimates mortality rates in clinical trials: results from REVIVE I & II
por: Thakkar, R, et al.
Publicado: (2007)

Effect of levosimendan treatment on length of hospital and intensive care stay in the REVIVE I study
por: Johansson, S, et al.
Publicado: (2004)

Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure
por: Mebazaa, A, et al.
Publicado: (2004)

The calcium sensitizer levosimendan reduces the brain natriuretic peptide levels as compared with dobutamine in intensive care unit septic patients with decompensated heart failure
por: Michalopoulou, H, et al.
Publicado: (2007)

Relationship between B-type natriuretic peptide plasma levels and echocardiography parameters in decompensated chronic heart failure patients treated with levosimendan
por: Ferri, MB, et al.
Publicado: (2006)

Newer treatments for decompensated heart failure: focus on levosimendan
por: Follath, Ferenc
Publicado: (2009)

Hemodynamic effects of levosimendan in patients with low-output heart failure
por: Gharsallah, H, et al.
Publicado: (2008)

Effects of levosimendan in acute heart failure, cardiogenic and septic shock
por: Alhashemi, JA, et al.
Publicado: (2008)

Levosimendan in trauma patients with acute cardiac failure
por: Afonin, AN, et al.
Publicado: (2011)

Retrospective study of proarrhythmic effects of levosimendan during the therapy of heart failure
por: Zima, E, et al.
Publicado: (2007)

Hemodynamic effects of the new calcium sensitiser levosimendan in cardiosurgical ICU patients
por: Iasonidou, C, et al.
Publicado: (2004)

Levosimendan Plus Dobutamine in Acute Decompensated Heart Failure Refractory to Dobutamine
por: Juguet, William, et al.
Publicado: (2020)

Implication on the prognosis according to the cause of heart failure decompensation
por: MB Silva, Pedro Gabriel, et al.
Publicado: (2015)

Efficacy of levosimendan in shock
por: McLean, A, et al.
Publicado: (2004)

Levosimendan in cardiac surgery
por: Harjola, V, et al.
Publicado: (2004)

Preoperative treatment with levosimendan helps to evaluate myocardial reserves in cardiosurgical patients with chronic heart failure
por: Eremenko, A, et al.
Publicado: (2015)

Established renal markers for diagnosis and prognosis in acutely decompensated heart failure
por: Brand, M, et al.
Publicado: (2015)

Levosimendan: experience of an adult ICU
por: Lippett, S, et al.
Publicado: (2006)

Is anemia a predictor of inhospital complications and mortality in decompensated heart failure?
por: Rocha, RM, et al.
Publicado: (2005)

Combined effects of ivabradine with dobutamine or levosimendan in isolated perfused hearts
por: Konrad, D, et al.
Publicado: (2013)

Use of levosimendan in myocardial dysfunction due to sepsis
por: Vaitsis, J, et al.
Publicado: (2009)

Levosimendan versus dobutamine in septic shock
por: Alhashemi, JA, et al.
Publicado: (2009)

Levosimendan versus dobutamine in cardiac surgery
por: Delgado-Amaya, MD, et al.
Publicado: (2015)

Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers
por: Bergh, Claes-Håkan, et al.
Publicado: (2010)

Influence of renal dysfunction on inhospital morbidity and mortality of patients with decompensated heart failure
por: Rocha, RM, et al.
Publicado: (2005)

Acute Decompensated Heart Failure Update
por: Teerlink, John R, et al.
Publicado: (2015)

Influence of temperature on the cardiac action of dobutamine and levosimendan in isolated perfused hearts
por: Aldenhoff, U, et al.
Publicado: (2013)

Levosimendan in critically ill adults: a utilisation review
por: Aron, J, et al.
Publicado: (2013)

Treatment of calcium channel blocker overdose with levosimendan
por: Sencan, A, et al.
Publicado: (2011)

Levosimendan versus dobutamine in Tako-tsubo cardiomyopathy
por: Righetti, FR, et al.
Publicado: (2013)

Levosimendan in myocardial depression due to severe sepsis
por: Malik, M, et al.
Publicado: (2007)

Haemodynamic effects of levosimendan following cardiac surgery
por: Slezina, A, et al.
Publicado: (2009)

Utilization of levosimendan in the cardiac ICU: case series
por: Filipescu, D, et al.
Publicado: (2009)

Hyponatremia is associated with increased mortality in patients with acute decompensated hear failure
por: Vaitsis, J, et al.
Publicado: (2009)

Levosimendan improves hemodynamic effects in patients with acutely decompensated heart failure: the Argentinean multicenter registry
por: Perrone, SV, et al.
Publicado: (2003)

Single-center experience with levosimendan in children undergoing cardiac surgery and in children with decompensated heart failure
por: Suominen, Pertti K
Publicado: (2011)

The effects of levosimendan use on high-sensitivity C-reactive protein in patients with decompensated heart failure
por: Korkmaz, Hasan, et al.
Publicado: (2019)

Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure
por: Njoroge, Joyce N., et al.
Publicado: (2021)

Relationship between B-type natriuretic peptide plasma levels and echocardiography parameters in compensated chronic heart failure patients treated with levosimendan
por: Figueiredo, EJ de Almeida, et al.
Publicado: (2007)

Short-term hemodynamic effects of nebivolol in acute decompensated heart failure: a randomized clinical trial
por: Puig, R, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_gvju969n3j7kajltgadimi8mh9